LYCOS RETRIEVER 
Pharmaceuticals: Company
built 178 days ago
CORONA, Calif., Sept. 4 /PRNewswire-FirstCall/ — Watson Pharmaceuticals, Inc. (NYSE:WPI) , a leading specialty pharmaceutical company, announced today that it has received its first U.S. Food and Drug Administration (FDA) product approval at its Goa, India facility. During the next several months the company plans to seek FDA approval to manufacture additional solid dosage […]
Source:
CORONA, Calif., February 13, 2008 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration ("FDA") has initiated an inspection of the company's Florida facilities. No information regarding the duration or outcome of the inspection is known.
Source:
NEW YORK, NY NOV 8, 2006 - Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that it has expanded the clinical trial sites for its ongoing Phase 2a study of oral Oleoyl-estrone (OE) in obese adult subjects to the United States. OE is the Company's orally administered product candidate in development for the treatment of obesity.
Source:
IntePharm is an emerging producer of pharmaceuticals, specialty compounds for the pharmaceutical, nutraceutical and functional food and beverage industries. In addition to manufacturing products, IntePharm discovers and develops more efficient and cost-effective manufacturing and mineral delivery processes. These processes are developed using a comprehensive technology platform that combines metabolic engineering, cellular genetics, advanced bioprocess engineering, and computer simulation science. The company owns several other pending patents for new products and technologies for immediate commercialization in food and nutritional products market.
Source:
NEW YORK, July 20 /PRNewswire/ -- The American Stock Exchange® (Amex®) today listed the common stock of Javelin Pharmaceuticals, Inc. under the ticker symbol JAV. Javelin is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target the moderate-to-severe pain medication market segment.
Source:
/PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that the Company had paid interest due February 15, 2008 on its 7.75% Convertible Senior Notes due 2012 (the "Notes"). The aggregate principal amount of the Notes is $60 million.
Source:
MORE ABOUT
Company